Your browser doesn't support javascript.
loading
Nanoparticulate paclitaxel demonstrates antitumor activity in PC3 and Ace-1 aggressive prostate cancer cell lines.
Axiak-Bechtel, Sandra M; Kumar, Senthil R; Dank, Kristin K; Clarkson, Nicole A; Selting, Kim A; Bryan, Jeffrey N; Rosol, Thomas J; Espinosa, Jahna; Decedue, Charles J.
Affiliation
  • Axiak-Bechtel SM; Comparative Oncology and Epigenetics Laboratory, Department of Veterinary Medicine and Surgery, University of Missouri, 900 East Campus Drive, Columbia, MO, 65211, USA, bechtels@missouri.edu.
Invest New Drugs ; 31(6): 1609-15, 2013 Dec.
Article in En | MEDLINE | ID: mdl-24026433
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Paclitaxel / Nanoparticles / Antineoplastic Agents, Phytogenic Limits: Animals / Humans / Male Language: En Journal: Invest New Drugs Year: 2013 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Paclitaxel / Nanoparticles / Antineoplastic Agents, Phytogenic Limits: Animals / Humans / Male Language: En Journal: Invest New Drugs Year: 2013 Document type: Article Country of publication: